“Nocebo effect” accounts for 76% of all adverse events in the COVID-19 vaccine trial group

The placebo effect is a phenomenon known to improve a person’s physical or mental health after taking a treatment with no pharmacological benefit – a sugar pill, or a syringe filled with saline, for example. While the biological, psychological, and genetic underpinnings of the placebo effect are not well understood, some theories point to expectations … Read more

Ketamine plus psychological therapy can help people stay off alcohol for longer time

People with severe alcohol use disorder were able to stay off alcohol for longer when treated with low doses of ketamine with psychotherapy in a clinical trial. The University of Exeter led the Ketamine Alcohol Relapse Reduction Trial (KARE) and was funded by the Medical Research Council. The phase two trial is the first of … Read more

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary results from Penn Medicine in an ongoing first-ever human clinical trial examining the safety, tolerability, and feasibility of macrophage chimeric antigen (CAR-M) have helped demonstrate the feasibility of this innovative immunotherapy, which advances the scientific groundbreaking discovery of CAR T-cell therapy. In Penn- for Solid Cancer Tumors and presents a promising new strategy in … Read more

Methamphetamine use may be two to four times higher than previously estimated

Researchers at the University of Queensland found that methamphetamine use can be two to four times higher than figures estimated in national surveys. Dr. Gary Chan from the University of Queensland National Center for Research on Drug Use in Young People He said the research investigated data collected between 2001 and 2019 and examined lifelong … Read more

New oral pill for COVID-19 home treatment

The continued emergence of novel and potentially threatened SARS-CoV-2 variants, the latest of which is the highly pathogenic Omicron variant (VOC), is evidence that the coronavirus 2019 (COVID-19) pandemic is far from over, although The massive spread of vaccines. As cases and hospitalizations continue to rise in many countries, new treatments are being sought to … Read more

SGLT2 inhibitor empagliflozin can be used to treat insulin resistance in the brain, finds study

Overweight or obesity, unwanted distribution of body fat and the development of type 2 diabetes are often associated with a decreased effect of the hormone insulin in many organs, including the brain (insulin resistance). So far there is no treatment to restore insulin sensitivity in the brain, which plays a key role in controlling metabolism. … Read more

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from the Clinical Trials Alliance in Oncology randomized clinical trials of adults with relapsing multiple myeloma in frontline treatment of lenalidomide show that adding ixazomib (Ninlaro┬«) to pomalidomide and dexamethasone as part of second-line treatment prolonged the time patients lived before being treated. . Exacerbation of disease (progression-free survival) compared to patients who … Read more

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Single dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptoms of COVID-19 and 91.7% effective against severe COVID-19 disease onset 28 days after vaccination, according to a randomized phase 3 Censored trial published in scalpel. The report indicates that Ad5-nCoV is safe, with no serious vaccine-related adverse events or … Read more

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a synthetic short chain of chemically modified nucleotides engineered at the Institute of RNA Therapeutics at UMass Chan School of Medicine, Robert H. The ALS gene known as C9ORF72 in a pilot study of a single patient. C9ORF72 is the most common cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). … Read more

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the start of a phase II clinical study of VK-2019 in patients with advanced Epstein-Barr Carcinoma (EBV)-nasopharyngeal carcinoma (NPC) and lymphoma. The study, which is being led by researchers at Stanford University School of Medicine, will include patients who have recurred, progressed after standard treatment, or who have not responded to … Read more